According to the current glioma classification (WHO 2021), GBMs correspond to IDH-wild-type diffuse and astrocytic gliomas that present at least one of the following features: microvascular proliferation, TERT promoter mutation, EGFR gene amplification or 7+/10− chromosome copy number changes [3]. This evidence concerns the gene IDH1 and central nervous system cancer.